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 Background Esophageal adenocarcinoma (EA) is an increasingly common cancer with poor survival. Barrett’s esophagus (BE) 
is the main precursor to EA, and every year 0.12% to 0.5% of BE patients progress to EA. BE typically arises on a 
background of chronic gastroesophageal reflux (GERD), one of the risk factors for EA.
 Methods We used genome-wide association data to investigate the genetic architecture underlying GERD, BE, and EA. 
We applied a method to estimate the variance explained (array heritability, h2g) and the genetic correlation (rg) 
between GERD, BE, and EA by considering all single nucleotide polymorphisms (SNPs) simultaneously. We also 
estimated the polygenic overlap between GERD, BE, and EA using a prediction approach. All tests were two-
sided, except in the case of variance-explained estimation where one-sided tests were used.
 Results We estimated a statistically significant genetic variance explained for BE (h2g = 35%; standard error [SE] = 6%; 
one-sided P = 1 × 10−9) and for EA (h2g = 25 %; SE = 5%; one-sided P = 2 × 10−7). The genetic correlation between 
BE and EA was found to be high (rg  =  1.0; SE  =  0.37). We also estimated a statistically significant polygenic 
overlap between BE and EA (one-sided P = 1 × 10−6), which suggests, together with the high genetic correlation, 
that shared genes underlie the development of BE and EA. Conversely, no statistically significant results were 
obtained for GERD.
 Conclusions We have demonstrated that risk to BE and EA is influenced by many germline genetic variants of small effect and 
that shared polygenic effects contribute to risk of these two diseases.
  J Natl Cancer Inst;2013;105:1711–1718 
Esophageal adenocarcinoma (EA) is a fatal cancer with a lifetime 
risk of approximately 0.25% (1,2) and a rapidly increasing inci-
dence in much of the developed world. The mortality rate for 
EA is high, with less than 20% of patients surviving 5 years (3). 
The main precursor to EA is Barrett’s esophagus (BE), which is 
defined as a metaplastic change of the normal stratified squa-
mous epithelium of the esophagus to columnar epithelium-con-
taining goblet cells (4). Recent estimates suggest that 0.12% to 
0.5 % of BE cases progress to EA per year (5–7), and clinical 
guidelines recommend surveillance for persons with BE, with the 
goal of identifying cancers at an early stage when they have a 
higher probability of cure (7). BE typically arises in patients with 
chronic gastroesophageal reflux (GERD), one of the risk factors 
for EA (8).
Observational studies indicate that a number of factors, includ-
ing GERD, cigarette smoking, obesity, and Heliobacter pylori CagA 
seronegativity account for the majority of EA cases, estimated at 
76% to 79% (9,10). However, there is emerging evidence for an 
important contribution of genetic factors as well to the etiology 
of EA and its precursors. Case reports, familial clusters, and clini-
cal series all have suggested that variations in GERD, BE, and EA 
risk are underpinned at least in part by genetic factors (11,12). 
Some studies have suggested that the three conditions may share a 
genetic background, because risk is increased for GERD, BE, and 
EA when a relative is affected with any one of the three (13–15). 
Larger studies of EA and its precursors have also suggested a 
genetic underlying component (16,17), and previous twin studies 
estimated a moderate heritability of GERD (30%–40%) (18,19).
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A recently published genome-wide association study (GWAS) 
of BE found common variants at the MHC locus and at chromo-
some 16q24.1 (20), although as in other complex diseases (21), the 
variants only explain a small proportion of the genetic variance. 
No GWASs on GERD and EA have been published to date. It is 
important to consider, however, that even if the individual effect 
size at any given single nucleotide polymorphism (SNP) is small, 
collectively these SNPs could still account for a substantial propor-
tion of variation in risk (22,23). Therefore, studies of combined risk 
alleles throughout the genome might identify individuals at higher 
risk for disease (24).
One way to investigate the extent of genetic contribution to dis-
ease is to estimate the heritability (h2), usually defined as the pro-
portion of total phenotypic variation that is due to additive genetic 
factors, from family history (pedigree data). With this traditional 
pedigree-based method, phenotypic similarity is related to expected 
allele sharing across the genome among family members. A novel 
way of measuring the genetic variance explained in “unrelated” 
individuals (h2g), which is the case for most human population stud-
ies, is to use information from genetic markers as an alternative to 
“expected sharing” among family members (25). Estimating h2g in 
unrelated individuals by including all SNPs with even a small asso-
ciation with disease can help us understand the genetic architecture 
behind disease. Yang et al. have shown that it is possible to estimate 
the realized genetic relationship between unrelated individuals (in 
the conventional sense) from dense SNP data (25).
To estimate the proportion of variation explained—h2g by all 
markers in case–control studies for GERD, BE, and EA—we used 
a recently developed software program, Genome-wide Complex 
Trait Analysis (GCTA) (26). We also investigated whether GERD, 
BE, and EA share a similar genetic background using two methods. 
The first method estimates genetic correlations from unrelated 
individuals (rather than families), thereby avoiding confounding 
by shared environment. The second method uses a large number 
of autosomal SNPs associated with one trait to predict the risk of 
developing the other trait (22).
Methods
The datasets used are summarized in Table 1, and a detailed sum-
mary of the BE and EA data can be found in Supplementary Table 1 
(available online).
For EA and BE case subjects (and associated control subjects), 
we used data and samples collected by investigators in the Barrett’s 
and Esophageal Adenocarcinoma Consortium (BEACON). We 
selected a subset of individuals with white-European ancestry from 
14 epidemiological studies from three continents. After exclusions, 
1509 EA case subjects, 2383 BE case subjects, and 2170 control 
subjects, typed for 797 518 SNPs, were used for analysis.
GERD analyses used a subset of unrelated white-European indi-
viduals from two twin studies, the Screening across the Lifespan 
Twin Study in the nationwide Swedish Twin Registry (27) and the 
UK St Thomas Adult Twin Registry (28). The Swedish data were 
used for estimating the variance explained as well as the genetic cor-
relation, and a combined dataset (Sweden + United Kingdom) was 
used for the polygenic overlap estimates. We only had summary data 
for the UK samples, and these could therefore only be used for the 
polygenic overlap analysis. Swedish samples were genotyped on the 
Illumina Omni Express (Illumina Inc, San Diego, CA). After exclu-
sions, 994 GERD case subjects and 1342 control subjects, typed for 
643 277 SNPs were included from this study. The UK samples were 
genotyped on the Illumina 660 array. After exclusions, 451 GERD 
cases and 1007 controls, typed for 551 049 SNPs were included from 
this study. After exclusions, the combined GERD dataset (Sweden + 
United Kingdom) included 1445 GERD case subjects and 2349 
control subjects, typed for 547 971 SNPs.
Statistical Methods
Individuals were excluded to ensure that no pairs had an estimated 
genetic relationship greater than 0.025 (approximately a second-
cousin relationship). Such individuals were excluded to avoid the 
possibility that the phenotypic resemblance between close relatives 
could be because of nongenetic effects (for example, shared envi-
ronment). Estimates of variance explained by all SNPs can be biased 
by genotyping errors, and we therefore applied a stricter quality 
control than for typical GWAS analyses (details in Supplementary 
Methods, available online). Variance explained for the X chromo-
some was estimated separately from the autosomes, under both full 
dosage (correcting for one X chromosome turned off in females) 
and no dosage compensation models. Twenty eigenvectors (princi-
pal components) were calculated using GCTA (26) and included as 
covariables to capture variance due to population stratification. Sex 
was included as a covariable for all disease traits, and continent of 
sample origin (Europe, North America, and Australia) was included 
as a covariable for BE and EA.
We used GCTA to calculate one genetic relationship matrix for 
the autosomal chromosomes (1–22) and another for the X chromo-
some. All three diseases were coded as binary traits (case–control 
status). The estimated variance explained was transformed from 
the observed scale to the unobserved continuous “liability” scale 
using a probit transformation. The continuous scale is independent 
of the incidence of each category and can therefore be compared 
across traits or populations (26). Phenotypes were modeled as a lin-
ear function of the sum of the additive effects due to all SNPs asso-
ciated with trait-associated variants and residual effects. Variance 
components were estimated by residual maximum likelihood (26). 
For tests for whether a variance component is zero or not, the test 
is one sided, and under the null hypothesis the test statistic fol-
lows a 50:50 mixture of a point mass at zero and the χ1 distribution 
Table 1. Summary of datasets used for chronic gastroesophageal 
reflux (GERD) (Swedish Twin Registry + UK Twin Registry), Barrett’s 







 Sweden 994 1342 643 277 Illumina Omni Express
 UK 451 1007 551 049 HumanHapmap 660
 GERD total 1445 2349 547 971
BE 2383 2167 797 518 Omni1-Quad
EA 1509 2170 797 518 Omni1-Quad
* A detailed summary of raw data is given in Supplementary Table 1 (available 
online). SNP = single nucleotide polymorphism.
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(29). In our GCTA analysis, one-sided tests were performed for 
the significance of the autosomal and the sex chromosome–specific 
variance-explained estimates.
Case–control studies usually have a much larger proportion of 
case subjects than do general populations, and we therefore needed 
to correct for disease prevalence/lifetime risk. Prevalence is suit-
able for conditions that are not fatal, but for cancer, lifetime risk 
is a more suitable measure of how the case–control sets differed 
from a random sample of subjects. For lifetime risk estimates, we 
used 1.6% for BE (30), 0.25% for EA (1,2) and 18% for GERD 
(31). Because of the uncertainty around these estimates, sensitivity 
analyses were performed to assess the robustness of the estimates 
of variance explained (Supplementary Methods, available online).
Genetic correlation measures the proportion of genetic vari-
ance that two traits share because of genetic causes. Traditionally, 
genetic correlations are estimated between quantitative traits in 
pedigree studies, which can be confounded by shared environmen-
tal factors. For disease traits with low prevalence, even if the true 
genetic correlation is high between diseases, coaggregation of disor-
ders in families might not occur or be distinguishable from chance. 
Here, we estimated the genetic correlation (rg) between all three 
traits using a bivariable mixed-effects linear model implemented 
in GCTA (32). The genetic correlation is the estimated additive 
genetic covariance between traits normalized by the geometric 
mean of the individual trait genetic variances (possible values of −1 
to +1). The additive genetic covariance was estimated by relating 
trait covariances between unrelated individuals to genetic relation-
ship estimates from marker data. That is, information comes from 
the covariance between individuals from different studies (eg, BE 
and EA). A higher covariance between traits with higher genetic 
relationship values implies a higher genetic correlation between 
traits. Case–control status was transformed to the underlying lia-
bility scale (33), as described previously for variance explained. To 
ensure no bias due to shared BE and EA control subjects in the per-
disease analysis, control subjects were divided between BE and EA 
and matched with case subjects from the same continent.
Trait prevalence is higher in males than females for both BE 
(34) and EA (35). To investigate differences between sexes in vari-
ance of liability captured by SNPs, we also fit a bivariable model for 
sex where male case subjects and male control subjects were used as 
the first trait and female case subjects and female control subjects 
were used as the second trait. A high genetic correlation between 
the trait in males and the trait in females implies little or no sex-
specific genetic effects.
We also investigated whether GERD, BE, and EA share a simi-
lar genetic background by using a large number of autosomal SNPs 
in one trait to predict the risk of developing the other trait (22). 
This method of prediction analysis has previously been used and 
published for other complex diseases such as schizophrenia and 
bipolar disorder (22) and endometriosis (36). Systematic evalua-
tion of the overlap between the traits was based on profile scores, 
for which we estimated the relative risk for each SNP of interest 
based on a discovery set (eg, BE), with this profile and then tested 
in a target set of interest (eg, EA). Profiles were constructed using 
varying proportions of SNPs (top 10% P values, top 20%, and 
so on). Continent of sample origin, sex, and the first 20 principal 
components were used as covariables in the logistic regression for 
both the discovery set analysis and the target set analysis. Control 
subjects were divided between BE and EA and matched with case 
subjects from the same continent.
In the target sample logistic regression analysis, variance 
explained in disease status by the profile score was quantified using 
the difference in the Nagelkerke’s pseudo R2 for the model includ-
ing the score vs a model without the score (37). We refer to this 
variance explained as R2.
Previous studies have shown that smoking, a high body mass 
index (BMI) and a large waist-to-hip ratio (WHR) are risk factors 
for GERD, BE, and EA (38–44). We therefore stratified BE and EA 
cases by smoking history (never smoked or smokers), BMI (lean/
normal BMI ≤ 25 kg/m2, overweight BMI > 25 and ≤ 30 kg/m2, 
obese BMI > 30  kg/m2) and WHR (lean WHR ≤ 0.9 and obese 
WHR > 0.9). Males are over-represented in our data, and a WHR 
threshold for males was therefore used. We did not have the covari-
able data to allow us to stratify the GERD twin samples.
results
We found that both BE and EA have a statistically significant poly-
genic component underlying disease risk. Autosomal h2g estimates 
were 35% (standard error [SE] = 6%; one-sided P = 1 × 10−9) for BE 
and were 25% (SE = 5%; one-sided P = 2 × 10−7) for EA (Table 2). 
We also estimated a small but statistically significant h2g for the X 
chromosome for EA (1.6%; SE = 1%; one-sided P = .04) (Table 3). 
Statistically significant results were not obtained for GERD, where 
wide 95% confidence intervals (0% to 42%; SE  =  21%) only 
allowed us to exclude a heritable component greater than 42% 
(Table 2) in this dataset.
The bivariable analysis showed a strong genetic correlation 
between BE and EA (rg = 1.0; SE. = 0.37) (Table 4), which means 
that BE and EA share a large proportion of common genes. We 
also estimated a strong genetic correlation (rg = 0.96; SE = 0.52) 
Table  2. Estimates of proportion of variation due to common 
genetic variants for chronic gastroesophageal reflux (GERD), 







explained h2g (SE) P
GERD† 994 1342 0.0 (0.21)‡ .50
BE 2255 1958 0.35 (0.06) 1 × 10−9
EA 1397 1947 0.25 (0.05) 2 × 10−7
* Proportion of variation and associated P values for the likelihood ratio test 
were estimated using a linear mixed model incorporating 797 518 single 
nucleotide polymorphisms for BE and EA and 643 277 single nucleotide 
polymorphisms for GERD from the genome-wide association studies panel 
after additional quality control. Case and control subject numbers are lower 
than for the original genome-wide association study because of stricter quality 
control (removal of related individuals and individuals with missing genotypes 
greater than 1%). SE = standard error.
† GERD included only Swedish data.
‡ The large standard error for GERD relative to, for instance, EA is because 
of the variance explained being scaled by a different life time risk (0.18 vs 
0.0025). One from each pair of individuals with a relationship greater than 
0.025 (between and within control and case subjects) were excluded, which 
is why the number of individuals for BE (removed n = 128), EA (removed 
n = 112), and controls (removed nBE = 209, nEA = 220) differ compared with 
Table 1.
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between males and females for BE, suggesting that the majority of 
genes underlying risk in males also influence risk in females, even 
though male cases were over-represented (35,45) (Table  5). The 
male–female correlation was also close to one for EA, but with a 
high standard error because of limited sample size (Table 5). Again, 
these analyses did not provide any statistically significant results for 
GERD, with a predicted null genetic variance (Table 2) precluding 
a reliable estimate of genetic correlation between GERD and BE 
and GERD and EA (Table 4).
We estimated a statistically significant polygenic overlap 
between BE and EA (one-sided P = 1 × 10−6). The polygenic profile 
score estimated from a large number of SNP effects in BE (>20% 
of all SNPs) explains 1.2% of the variance in EA (Figure  1A). 
Predicting whether the reverse is true, where SNPs associated with 
EA are used to predict risk of BE, suggests a lower genetic over-
lap of approximately 0.5% (Figure 1B). This is primarily because 
estimates for each SNP from the association study when using 
EA as a discovery set were less accurate because the EA dataset is 
smaller. The prediction analysis showed no overlap between BE 
and GERD or EA and GERD (Figure 1, C and D). Although the 
statistical power decreased using smaller subsets of the data, we 
observed an increase in the polygenic overlap among cases with 
low BMI (≤25 kg/m2) when using EA to predict BE (2%) (Table 6).
Discussion
Rates of EA have been rising rapidly during the past three decades 
in most Western countries, suggesting strong environmental influ-
ences on incidence. However, changes in trait means do not pre-
clude there being substantial variance due to genetic factors [one 
simple quantitative trait example would be human height, where 
despite increases in mean height throughout the 20th century, the 
mean difference between countries remained stable and trait vari-
ance and heritability estimates are broadly similar across countries 
(46)]. A likely explanation, compatible with our data, is that suscep-
tibility to BE/EA is not distributed in the population uniformly. 
Rather, some people have higher susceptibility than others because 
of their genetic load, which in the context of changing environ-
mental conditions increases their absolute risk of cancer.
Traditional heritability estimates from twin studies differ from 
these analyses in two ways. First, in the case where expected sharing 
is used among (close) family members, all of the genome contrib-
utes to the estimate of h2. In contrast, estimating the genetic rela-
tionship between unrelated individuals uses information on only 
the portion of the genome tagged by SNPs on the array used. This 
makes h2g a lower bound for h2 (33). Second, twin studies typically 
sample from the general population and hence provide heritability 
estimates for the condition up to the age at which the twins were 
ascertained (47). Twin studies generally, but not always, ascertain 
individuals who are aged less than 85 years. In contrast, we assumed 
that lifetime risk (up to age 85 years) was of primary interest for our 
h2g calculations.
The method implemented in GCTA depends upon specifica-
tion of prevalence of the trait in the population—essentially one 
has to parameterize how different the case–control sample would 
be from a randomly drawn sample from the general population. 
The general population has a lifetime risk of esophageal cancer 
approximating 0.5% (1,2,48,49). This estimate is inclusive of both 
major histological types of cancer of the esophagus: esophageal ade-
nocarcinoma and esophageal squamous cell carcinoma, which dif-
fer in epidemiology, risk factors, and presumed pathogenesis. The 
adenocarcinoma subtype accounts for 50% or more of esophageal 
cancer cases in North America and Western Europe (1–3), whereas 
esophageal squamous cell carcinoma is the predominant form 
worldwide and accounts for 90% of all esophageal cancers (50,51). 
In this study, we used a lifetime risk estimate of 0.25% for esopha-
geal adenocarcinoma, which could be an underestimate because 
our samples were obtained from different parts of the developed 
world; however, although estimates of variance explained require 
specification of the lifetime risk, they are relatively robust to mis-
specification of this parameter (26).
The main aim of the polygenic overlap analysis is not to predict 
risk but to evaluate the influence of many common variants of small 
effects on risk of disease and to assess the overlap between diseases. 
A  polygenic trait is defined as a trait influenced by many genes. 
The polygenic overlap prediction estimates of variance explained 
(R2) are low because of each individual SNP being estimated with 
substantial error from the association study. These estimates are 
Table  4. Bivariable analysis for gastroesophageal reflux (GERD), 







(trait 1/2) rg (SE)
BE/EA 1986/1403 789/1175 1 (0.37)
BE/GERD† 1982/934 787/1282 NA‡
EA/GERD† 1400/928 1167/1283 NA‡
* Results shown in bold are statistically significantly different from zero. One 
from each pair of individuals with a relationship greater than 0.025 (between 
and within controls and cases for both traits) were excluded (ie, within BE/EA 
(removed nBE = 397, nEA = 105), BE/GERD (removed nBE = 401, nGERD = 60) and 
EA/GERD (removed nEA = 109, nGERD = 66). rg = estimated genetic correlation; 
SE = standard error.
† GERD included only Swedish samples.
‡ Because the additive genetic variance was estimated to be zero for GERD, we 
could not estimate the genetic correlation for BE/GERD or EA/GERD.
Table  3. Estimates of proportion of variation due to common 
genetic variants by the X chromosome for chronic gastroesopha-







Proportion of  
variance (SE)†
dc0 dc1
GERD‡ 994 1342 0.0 (0.04) 0.0 (0.02)
BE 2255 1958 0.01 (0.01) 0.007 (0.006)
EA 1397 1947 0.016 (0.01) 0.013 (0.008)
* One from each pair of individuals with a relationship greater than 0.025 
(between and within control and case subjects) were excluded, reducing 
the number of participants as follows: BE (removed n = 128), EA (removed 
n = 112) and controls (removed nBE = 209, nEA = 220). SE = standard error.
† For proportion of variance, dc1 is the estimate corrected for full dosage score 
and dc0 is not corrected. Bold results are statistically significantly different 
from zero.
‡ GERD included only Swedish data.
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also constrained to be not more than the total genetic variance 
(heritability) for the trait. However, the estimated overlap is highly 
statistically significant for BE/EA and clearly shows that both traits 
have a polygenic architecture (because the variance explained con-
tinues to rise as one goes from the top 1% of SNPs to the top 
20% of SNPs etc, implying that many SNPs contribute) as well as 
a shared genetic background. A new method with greater flexibility 
than GCTA in terms of modeling large effect loci (in addition to 
small effect loci under the infinitesimal model) was recently pub-
lished (52). However, for this study, we assumed an infinitesimal 







h2g (SE),  
males only
h2g (SE),  
females only
rg (SE),  
males/females
GERD† 429/584 565/758 0.17 (0.47) 0.0 (0.36) NA‡
BE 1495/1542 486/422 0.37 (0.08) 0.30 (0.26) 0.96 (0.52)
EA 1239/1541 165/415 0.26 (0.06) 0.30 (0.36) 1 (0.85)
* One from each pair of individuals with a relationship greater than 0.025 (between and within controls and case subjects in both sexes) were excluded, which is why 
the number of individuals for BE, EA, and controls differ compared with Table 1. h2g = estimated genetic variance explained; rg = estimated genetic correlation; 
SE = standard error.
† GERD included only Swedish samples.
‡ Because the additive genetic variance was estimated to be zero for GERD in females we could not estimate the genetic correlation for GERD males/females.
Figure  1. Allele specific score prediction. A) Barrett’s esophagus (BE) 
predicts esophageal adenocarcinoma (EA). BE as discovery set and 
EA as target set. B) EA predicts BE. EA as discovery set and BE as the 
target set. C) Gastroesophageal reflux (GERD) (Sweden + UK datasets) 
predicts BE. D) GERD (Sweden + UK datasets) predicts EA. C and D) 
GERD as discovery set where (C) uses BE as target set and (D) uses EA 
as target set. Variance explained in the target dataset on the basis of 
allele-specific scores derived in the discovery dataset for eight statistical 
significance thresholds (x-axis). The y-axis indicates variance explained, 
based on Nagelkerke’s pseudo R2. The P value for the target dataset 
analysis is found above each bar. (A) and (B) show that the results are 
not driven by a few highly associated regions, indicating a substantial 
number of common variants underlying disease. SNP = single nucleo-
tide polymorphism.
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model for our traits of interest (where there was no evidence for a 
strong departure from the infinitesimal model; eg, through there 
being variants of large effect). Figure 1A shows that the R2 esti-
mate decreases when adding more than 40% of the top SNPs. This 
is because of the inclusion of less statistically significant P values, 
which represent noise.
Our GERD dataset was not informative enough to allow us to 
reach a conclusion on the array heritability for GERD—the 95% 
confidence interval (0% to 42%) overlapped with the traditional 
heritability estimates from twin studies (30%–40%) (18,19). Array 
heritability may represent an underestimation of heritability as 
compared with that calculated from twin studies because the latter 
also takes into account rare variants that are usually absent from 
genome-wide genotyping arrays. In other diseases, array heritability 
has been reported to be between a quarter and half of the herit-
ability estimated from twin studies (26). Our GERD study was less 
informative for estimating array heritability because, although the 
number of case subjects was similar to EA, the ascertainment was 
less extreme than EA (lifetime risk for EA = 0.0025 vs lifetime risk 
for reflux = 0.18). This is apparent in the standard error for GERD, 
which is approximately four times greater than the EA standard 
error, despite roughly similar sample sizes (0.21 and 0.05, respec-
tively). There is also a limitation of identifying GERD using a ques-
tionnaire, compared with clinically identifying BE and EA patients.
Given, the null estimate of array heritability, we were unable 
to reliably estimate a genetic correlation between GERD and EA 
or BE. As an alternative to examining possible polygenic overlap 
between GERD and EA and BE, we applied a prediction approach. 
Although this prediction approach showed a clear relationship 
between EA and BE (P =1 × 10−6), there was no statistically signifi-
cant prediction of GERD with EA or BE.
A longitudinal study for patients developing BE from GERD, 
EA from GERD, and EA from BE would be an ideal approach to 
estimating a genetic overlap between all three diseases. However, 
in the absence of this kind of data, we have shown that we can make 
useful inferences from the cross-sectional data collected here.
We have shown that the risks of BE and EA are influenced 
by genetic variants that are common in the population and that 
a large proportion of the genes associated with these two diseases 
are shared between them. These results emphasize the important 
role of genetic variants in BE and EA risk and suggest that future 
GWASs should consider combining these two disease types to cre-
ate larger sample sizes that may identify further genetic associations.
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